APO Research
Talk to an analyst

APO RESEARCH · REPORT

Leber's Hereditary Optic Neuropathy Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Leber's Hereditary Optic Neuropathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025183 pages

Choose your research edition.

Industry ResearchLeber's Hereditary Optic Neuropathy Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Leber's Hereditary Optic Neuropathy Drug Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Leber's Hereditary Optic Neuropathy Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Leber's Hereditary Optic Neuropathy Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Leber's Hereditary Optic Neuropathy Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Leber's Hereditary Optic Neuropathy Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Leber's Hereditary Optic Neuropathy Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Leber's Hereditary Optic Neuropathy Drug include Stealth BioTherapeutics Inc., Spark Therapeutics, Inc., Khondrion BV, Ixchel Pharma, LLC, GenSight Biologics S.A., Biovista Inc. and Alkeus Pharmaceuticals, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Leber's Hereditary Optic Neuropathy Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Leber's Hereditary Optic Neuropathy Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Leber's Hereditary Optic Neuropathy Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Leber's Hereditary Optic Neuropathy Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Leber's Hereditary Optic Neuropathy Drug Segment by Company

Stealth BioTherapeutics Inc.

Spark Therapeutics, Inc.

Khondrion BV

Ixchel Pharma, LLC

GenSight Biologics S.A.

Biovista Inc.

Alkeus Pharmaceuticals, Inc.

Leber's Hereditary Optic Neuropathy Drug Segment by Type

Elamipretide

KH-176

IXC-201

GS-011

Others

Leber's Hereditary Optic Neuropathy Drug Segment by Application

Hospital

Clinic

Others

Leber's Hereditary Optic Neuropathy Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leber's Hereditary Optic Neuropathy Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Leber's Hereditary Optic Neuropathy Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leber's Hereditary Optic Neuropathy Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Leber's Hereditary Optic Neuropathy Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Leber's Hereditary Optic Neuropathy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Leber's Hereditary Optic Neuropathy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Leber's Hereditary Optic Neuropathy Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Leber's Hereditary Optic Neuropathy Drug Industry Trends Table 2. Leber's Hereditary Optic Neuropathy Drug Industry Drivers Table 3. Leber's Hereditary Optic Neuropathy Drug Industry Opportunities and Challenges Table 4. Leber's Hereditary Optic Neuropathy Drug Industry Restraints Table 5. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Leber's Hereditary Optic Neuropathy Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Manufacturers Table 9. Global Leber's Hereditary Optic Neuropathy Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Leber's Hereditary Optic Neuropathy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Leber's Hereditary Optic Neuropathy Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Leber's Hereditary Optic Neuropathy Drug Manufacturers, Product Type & Application Table 13. Global Leber's Hereditary Optic Neuropathy Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Leber's Hereditary Optic Neuropathy Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Elamipretide Table 17. Major Manufacturers of KH-176 Table 18. Major Manufacturers of IXC-201 Table 19. Major Manufacturers of GS-011 Table 20. Major Manufacturers of Others Table 21. Global Leber's Hereditary Optic Neuropathy Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Type (2021-2026) Table 25. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Type (2027-2032) Table 26. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Type (2021-2026) Table 30. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Clinic Table 33. Major Manufacturers of Others Table 34. Global Leber's Hereditary Optic Neuropathy Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Application (2021-2026) Table 38. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Application (2027-2032) Table 39. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Application (2021-2026) Table 43. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Application (2027-2032) Table 44. Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Leber's Hereditary Optic Neuropathy Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Region (2021-2026) Table 47. Global Leber's Hereditary Optic Neuropathy Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Leber's Hereditary Optic Neuropathy Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Leber's Hereditary Optic Neuropathy Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Leber's Hereditary Optic Neuropathy Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Leber's Hereditary Optic Neuropathy Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Region (2021-2026) Table 65. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Region (2027-2032) Table 66. Stealth BioTherapeutics Inc. Company Information Table 67. Stealth BioTherapeutics Inc. Business Overview Table 68. Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 70. Stealth BioTherapeutics Inc. Recent Development Table 71. Spark Therapeutics, Inc. Company Information Table 72. Spark Therapeutics, Inc. Business Overview Table 73. Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 75. Spark Therapeutics, Inc. Recent Development Table 76. Khondrion BV Company Information Table 77. Khondrion BV Business Overview Table 78. Khondrion BV Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Khondrion BV Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 80. Khondrion BV Recent Development Table 81. Ixchel Pharma, LLC Company Information Table 82. Ixchel Pharma, LLC Business Overview Table 83. Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 85. Ixchel Pharma, LLC Recent Development Table 86. GenSight Biologics S.A. Company Information Table 87. GenSight Biologics S.A. Business Overview Table 88. GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 90. GenSight Biologics S.A. Recent Development Table 91. Biovista Inc. Company Information Table 92. Biovista Inc. Business Overview Table 93. Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 95. Biovista Inc. Recent Development Table 96. Alkeus Pharmaceuticals, Inc. Company Information Table 97. Alkeus Pharmaceuticals, Inc. Business Overview Table 98. Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio Table 100. Alkeus Pharmaceuticals, Inc. Recent Development Table 101. Key Raw Materials Table 102. Raw Materials Key Suppliers Table 103. Leber's Hereditary Optic Neuropathy Drug Distributors List Table 104. Leber's Hereditary Optic Neuropathy Drug Customers List Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. Leber's Hereditary Optic Neuropathy Drug Product Image Figure 2. Global Leber's Hereditary Optic Neuropathy Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Leber's Hereditary Optic Neuropathy Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Leber's Hereditary Optic Neuropathy Drug Sales (2021-2032) & (K Units) Figure 5. Global Leber's Hereditary Optic Neuropathy Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Leber's Hereditary Optic Neuropathy Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Elamipretide Image Figure 9. KH-176 Image Figure 10. IXC-201 Image Figure 11. GS-011 Image Figure 12. Others Image Figure 13. Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Type (2021-2032) Figure 16. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Application (2021-2032) Figure 25. Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Country (2021-2032) Figure 42. China Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Leber's Hereditary Optic Neuropathy Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Leber's Hereditary Optic Neuropathy Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Leber's Hereditary Optic Neuropathy Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Leber's Hereditary Optic Neuropathy Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Elamipretide
  • KH-176
  • IXC-201
  • GS-011
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Stealth BioTherapeutics Inc.
  • Spark Therapeutics, Inc.
  • Khondrion BV
  • Ixchel Pharma, LLC
  • GenSight Biologics S.A.
  • Biovista Inc.
  • Alkeus Pharmaceuticals, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Leber's Hereditary Optic Neuropathy Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Leber's Hereditary Optic Neuropathy Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Leber's Hereditary Optic Neuropathy Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Leber's Hereditary Optic Neuropathy Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Leber's Hereditary Optic Neuropathy Drug Market Dynamics
  1. 2.1 Leber's Hereditary Optic Neuropathy Drug Industry Trends
  2. 2.2 Leber's Hereditary Optic Neuropathy Drug Industry Drivers
  3. 2.3 Leber's Hereditary Optic Neuropathy Drug Industry Opportunities and Challenges
  4. 2.4 Leber's Hereditary Optic Neuropathy Drug Industry Restraints
3 Leber's Hereditary Optic Neuropathy Drug Market by Manufacturers
  1. 3.1 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Leber's Hereditary Optic Neuropathy Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Leber's Hereditary Optic Neuropathy Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Leber's Hereditary Optic Neuropathy Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Leber's Hereditary Optic Neuropathy Drug Manufacturers, Product Type & Application
  7. 3.7 Global Leber's Hereditary Optic Neuropathy Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Leber's Hereditary Optic Neuropathy Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Leber's Hereditary Optic Neuropathy Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Leber's Hereditary Optic Neuropathy Drug Tier 1, Tier 2, and Tier 3
4 Leber's Hereditary Optic Neuropathy Drug Market by Type
  1. 4.1 Leber's Hereditary Optic Neuropathy Drug Type Introduction
  2. 4.1.1 Elamipretide
  3. 4.1.2 KH-176
  4. 4.1.3 IXC-201
  5. 4.1.4 GS-011
  6. 4.1.5 Others
  7. 4.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Type
  8. 4.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type
  12. 4.3.1 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Type (2021-2032)
5 Leber's Hereditary Optic Neuropathy Drug Market by Application
  1. 5.1 Leber's Hereditary Optic Neuropathy Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Application
  6. 5.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Leber's Hereditary Optic Neuropathy Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application
  10. 5.3.1 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Application (2021-2032)
6 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region
  1. 6.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Leber's Hereditary Optic Neuropathy Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Leber's Hereditary Optic Neuropathy Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region
  1. 7.1 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region
  2. 7.1.1 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Leber's Hereditary Optic Neuropathy Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Leber's Hereditary Optic Neuropathy Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032)
  8. 7.2.2 North America Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032)
  11. 7.3.2 Europe Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Leber's Hereditary Optic Neuropathy Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Stealth BioTherapeutics Inc.
  2. 8.1.1 Stealth BioTherapeutics Inc. Company Information
  3. 8.1.2 Stealth BioTherapeutics Inc. Business Overview
  4. 8.1.3 Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Stealth BioTherapeutics Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  6. 8.1.5 Stealth BioTherapeutics Inc. Recent Developments
  7. 8.2 Spark Therapeutics, Inc.
  8. 8.2.1 Spark Therapeutics, Inc. Company Information
  9. 8.2.2 Spark Therapeutics, Inc. Business Overview
  10. 8.2.3 Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Spark Therapeutics, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  12. 8.2.5 Spark Therapeutics, Inc. Recent Developments
  13. 8.3 Khondrion BV
  14. 8.3.1 Khondrion BV Company Information
  15. 8.3.2 Khondrion BV Business Overview
  16. 8.3.3 Khondrion BV Leber's Hereditary Optic Neuropathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Khondrion BV Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  18. 8.3.5 Khondrion BV Recent Developments
  19. 8.4 Ixchel Pharma, LLC
  20. 8.4.1 Ixchel Pharma, LLC Company Information
  21. 8.4.2 Ixchel Pharma, LLC Business Overview
  22. 8.4.3 Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Ixchel Pharma, LLC Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  24. 8.4.5 Ixchel Pharma, LLC Recent Developments
  25. 8.5 GenSight Biologics S.A.
  26. 8.5.1 GenSight Biologics S.A. Company Information
  27. 8.5.2 GenSight Biologics S.A. Business Overview
  28. 8.5.3 GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GenSight Biologics S.A. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  30. 8.5.5 GenSight Biologics S.A. Recent Developments
  31. 8.6 Biovista Inc.
  32. 8.6.1 Biovista Inc. Company Information
  33. 8.6.2 Biovista Inc. Business Overview
  34. 8.6.3 Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Biovista Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  36. 8.6.5 Biovista Inc. Recent Developments
  37. 8.7 Alkeus Pharmaceuticals, Inc.
  38. 8.7.1 Alkeus Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Alkeus Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Alkeus Pharmaceuticals, Inc. Leber's Hereditary Optic Neuropathy Drug Product Portfolio
  42. 8.7.5 Alkeus Pharmaceuticals, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Leber's Hereditary Optic Neuropathy Drug Value Chain Analysis
  2. 9.1.1 Leber's Hereditary Optic Neuropathy Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Leber's Hereditary Optic Neuropathy Drug Production Mode & Process
  6. 9.2 Leber's Hereditary Optic Neuropathy Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Leber's Hereditary Optic Neuropathy Drug Distributors
  9. 9.2.3 Leber's Hereditary Optic Neuropathy Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst